NL-OMON45955已完成3 期
A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection. - REACT
The Kirby Institute, The University of New South Wales Australia0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible to participate in this study. ;1 Participants have voluntarily signed the informed consent form.
- •2 18 years of age or older.
- •3 Detectable HCV RNA at screening (>10,000 IU/ml), and in the opinion of the investigator is unlikely to demonstrate spontaneous viral clearance
- •4 HCV genotypes 1-6.
- •5 HBsAg negative
- •6 Negative pregnancy test at baseline (females of childbearing potential only).
- •7 Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- •8 Medically stable on the basis of physical examination, medical history and vital signs
- •9 Adequate literacy to provide reliable responses to the study questionnaires
- •10 All fertile males and females must be using effective contraception during treatment and during the 30 days after treatment end.
- •11 Recently acquired HCV infection (estimated duration of infection <=12 months)*;Recently acquired HCV infection as defined by:
- •i) First anti-HCV Ab or HCV RNA positive within the previous 6 months
- •ii) Documented anti-HCV Ab negative within the 12 months prior to anti-HCV antibody positive result ;OR ;B)
- •i) First anti-HCV Ab or HCV RNA positive within the previous 6 months
- •ii) Acute clinical hepatitis (jaundice or ALT> 10 X ULN) within the previous 6 months prior to first positive HCV antibody or HCV RNA, with no other cause of acute hepatitis identifiable;OR;C) For cases of recent HCV reinfection the following criteria are required:
- •Documented prior HCV antibody positive with HCV RNA negative on at least 2 occasions 6 months apart AND new HCV RNA positive within the previous 6 months ;*Estimated duration of infection based on midpoint between last antibody negative or HCV RNA and first antibody positive or HCV RNA in the case of seroconversion and 6 weeks prior to date of maximum ALT in the case of acute hepatitis.;If co-infection with HIV is documented, the subject must meet the following criteria:
- •1. Antiretroviral (ARV) untreated for >8 weeks preceding screening visit with CD4 T cell count >500 cells/mm3
- •2. On a stable ARV regimen for >8 weeks prior to screening visit, with CD4 T cell count >200 cells/mm3 and an undetectable plasma HIV RNA level.
- •Suitable ARV include:
- •o Nucleos(t)ide reverse transcriptase inhibitors: Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC)Non-nucleoside reverse transcriptase inhibitors: Rilpivirine
- •o Protease inhibitors: Atazanavir, darunavir, lopinavir, ritonavir
- •o Integrase inhibitors: Dolutegravir, raltegravir, elvitegravir/cobicistat
- •Contraindicated ARV include:
- •o Efavirenz
- •* - 50% reduction in velpatasvir (GS-5816) exposure
- •o Didanosine
- •o Zidovudine
- •o Tipranavir
- •Other ARV agents may be permissible at the time of study commencement pending further drug-drug interaction studies; please discuss with the Medical Monitor.
排除标准
- •Subjects who meet any of the exclusion criteria are not to be enrolled in this study.;1 History of any of the following:
- •a. Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with the participant treatment, assessment or compliance with the protocol; participants currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.
- •b. History of chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- •c. Solid organ transplant
- •d. Malignancy within 5 years prior to screening, with exception of specific cancers that may have been cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are also excluded.
- •e. Significant drug allergy (such as anaphylaxis or hepatotoxicity)
- •2. Subject has a known or documented prior history of cirrhosis
- •3 Subject shows evidence of significant liver disease in addition to hepatitis C, which may include but is not limited to drug- or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson*s disease, non-alcoholic steatohepatitis (NASH), or primary biliary cirrhosis
- •4 Any of the following lab parameters at screening:
- •a. Direct bilirubin > 1.5 x ULN
- •b. Platelets < 50,000/µL
- •c. Creatinine clearance (CLcr) < 50 mL/min
- •d. Haemoglobin < 10 g/dL
- •e. Albumin < 30g/L
- •f. International Normalised Ratio (INR) >1.5 (unless subject is on a stable anticoagulant regimen or has known coagulopathy)
- •5 Pregnant or nursing female
- •6 Use of prohibited concomitant medications as described in the study protocol
- •7 Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent > 10 mg/day)
- •8 Known hypersensitivity to velpatasvir, sofosbuvir or formulation excipients.
- •9 Therapy with any anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <=6 months prior to the first dose of study drug.
- •10 Any investigational drug <=6 weeks prior to the first dose of study drug.
- •11 Previous failure of therapy with sofosbuvir or an NS5A inhibitor prior to the first dose of study drug.
- •12 Ongoing severe psychiatric disease as judged by the treating physician.
- •13 Frequent injecting drug use that is judged by the treating physician to compromise treatment safety.
- •14 Inability or unwillingness to provide informed consent or abide by the requirements of the study.
- •15. Prior enrolment within this study.
研究者
相似试验
已完成
4 期
A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis1001965410003816Autoimmune hepatitisNL-OMON52983eids Universitair Medisch Centrum66
已完成
3 期
A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal bleeding from angiodysplasias.angiodysplasiavascular malformation10017959NL-OMON44271Maag-, darm- en leverziekten62
已完成
2 期
A randomised, controlled, double-blind trial to investigate the effects of a new infant formula on growth, tolerance and safety in healthy term infants.effect op de groei van zuigelingeneffects on growthNL-OMON39783utricia Research - Centre for Specialised Nutrition121
已完成
2 期
A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysmAbdominal aortic aneurysmdilation of the aorta in the abdomen10002363NL-OMON38947ovartis7
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemiahypertriglyceridemia10013317NL-OMON43654IONIS Pharmaceuticals, Inc6